JP7493449B2 - ステアリン酸マグネシウムを含む乾燥粉末組成物 - Google Patents

ステアリン酸マグネシウムを含む乾燥粉末組成物 Download PDF

Info

Publication number
JP7493449B2
JP7493449B2 JP2020516655A JP2020516655A JP7493449B2 JP 7493449 B2 JP7493449 B2 JP 7493449B2 JP 2020516655 A JP2020516655 A JP 2020516655A JP 2020516655 A JP2020516655 A JP 2020516655A JP 7493449 B2 JP7493449 B2 JP 7493449B2
Authority
JP
Japan
Prior art keywords
dry powder
powder composition
particles
dry
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502954A (ja
Inventor
ヤディディ、カンビズ
Original Assignee
ヴェクチュラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェクチュラ インコーポレイテッド filed Critical ヴェクチュラ インコーポレイテッド
Publication of JP2021502954A publication Critical patent/JP2021502954A/ja
Priority to JP2022098813A priority Critical patent/JP7561162B2/ja
Application granted granted Critical
Publication of JP7493449B2 publication Critical patent/JP7493449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0023—Mouthpieces therefor retractable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020516655A 2017-09-22 2017-09-26 ステアリン酸マグネシウムを含む乾燥粉末組成物 Active JP7493449B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022098813A JP7561162B2 (ja) 2017-09-22 2022-06-20 ステアリン酸マグネシウムを含む乾燥粉末組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562295P 2017-09-22 2017-09-22
US62/562,295 2017-09-22
PCT/US2017/053569 WO2019059953A2 (en) 2017-09-22 2017-09-26 DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022098813A Division JP7561162B2 (ja) 2017-09-22 2022-06-20 ステアリン酸マグネシウムを含む乾燥粉末組成物

Publications (2)

Publication Number Publication Date
JP2021502954A JP2021502954A (ja) 2021-02-04
JP7493449B2 true JP7493449B2 (ja) 2024-05-31

Family

ID=65200304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516655A Active JP7493449B2 (ja) 2017-09-22 2017-09-26 ステアリン酸マグネシウムを含む乾燥粉末組成物
JP2022098813A Active JP7561162B2 (ja) 2017-09-22 2022-06-20 ステアリン酸マグネシウムを含む乾燥粉末組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022098813A Active JP7561162B2 (ja) 2017-09-22 2022-06-20 ステアリン酸マグネシウムを含む乾燥粉末組成物

Country Status (9)

Country Link
US (3) US10195147B1 (https=)
EP (1) EP3684338A4 (https=)
JP (2) JP7493449B2 (https=)
KR (2) KR102681843B1 (https=)
CN (2) CN115919780A (https=)
AU (1) AU2017432640B2 (https=)
CA (1) CA3076353A1 (https=)
MX (2) MX2020002769A (https=)
WO (1) WO2019059953A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022137070A (ja) * 2017-09-22 2022-09-21 オティトピック インク． ステアリン酸マグネシウムを含む乾燥粉末組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013388034B2 (en) * 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
EP3393517B1 (en) * 2015-12-22 2021-08-11 AspiAir GmbH Acetylsalicylic acid for use in the treatment of moderate to severe influenza
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
WO2018222583A1 (en) 2017-05-30 2018-12-06 Rho Pharmaceuticals, Llc In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)
NL2021637B1 (en) * 2018-09-14 2020-05-07 Stichting Katholieke Univ Breath sampler
US20250268829A1 (en) * 2022-04-22 2025-08-28 Board Of Regents, The University Of Texas System Inhaled antibacterial formulations for treating lung infections
EP4721788A1 (en) * 2023-05-26 2026-04-08 Japan Tobacco Inc. Suction device and suction system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521788A (ja) 2004-11-30 2008-06-26 ヴェクトゥラ リミテッド 医薬製剤
JP2017506252A (ja) 2014-02-20 2017-03-02 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
JPS61140520A (ja) 1984-12-12 1986-06-27 Lion Corp アセチルサリチル酸製剤
FR2580634B1 (fr) 1985-04-19 1988-08-05 Rhone Poulenc Sante Nouveau derive de l'acide acetylsalicylique, sa preparation et les compositions pharmaceutiques qui le contiennent
DE3814856A1 (de) 1988-05-02 1989-11-16 Verla Pharm Mittel zur prophylaxe des herzinfarkts und zur verhuetung des reinfarkts
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US20070117862A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5533502A (en) 1993-05-28 1996-07-09 Vortran Medical Technology, Inc. Powder inhaler with aerosolization occurring within each individual powder receptacle
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
KR20010111564A (ko) 1998-11-12 2001-12-19 프랭크 쥐. 필키윅즈 흡입 시스템
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
US20030176421A1 (en) 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
NZ521034A (en) 2000-02-28 2004-08-27 Vectura Ltd Improvements in or relating to the delivery of oral drugs
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
EP1177805A1 (en) 2000-07-31 2002-02-06 Maryland Financial Inc. Powder inhaler
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002043702A2 (en) 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
MXPA03004340A (es) 2000-12-22 2005-01-25 Aspen Aerogels Inc Agentes terapeuticos en polvo de aerogel.
ATE255929T1 (de) 2001-03-05 2003-12-15 Ivo Pera Inhalationsvorrichtung zum dispergieren von in kapseln enthaltenen pulverförmigen medikamente durch den respirationstrakt
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
GB0129270D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
AU2003215334A1 (en) 2002-02-22 2003-09-09 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
US20040105821A1 (en) 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
GB0226105D0 (en) 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
CA2521394A1 (en) 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
JP4943838B2 (ja) 2003-04-09 2012-05-30 ネクター セラピューティクス 空気入口シールドを備えたエアゾール化装置
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
US7041286B2 (en) 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
EP1660428A1 (en) 2003-08-20 2006-05-31 Eli Lilly And Company Ppar modulators
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
JP5303605B2 (ja) * 2003-10-16 2013-10-02 第一三共ヘルスケア株式会社 サリチル酸類含有経口組成物
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
WO2005041886A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Methods for generating or increasing revenues related to pain inhibitor commerce
US20070232575A1 (en) 2004-02-05 2007-10-04 Baulieu Etienne E Treatment of Pulmonary Artery Hypertension with Dhea, Dheas, Dhea Analogs, or Dhea Derivatives
US20050187268A1 (en) 2004-02-23 2005-08-25 Prolexys Pharmaceuticals Inc. Non-peptidyl agents with pHSP20-like activity, and uses thereof
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
US7189750B2 (en) 2004-05-05 2007-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof
CA2567056A1 (en) 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2006017354A1 (en) 2004-07-13 2006-02-16 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain
MX2007001561A (es) 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
WO2006060117A2 (en) 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP2009502967A (ja) 2005-07-27 2009-01-29 ナステック ファーマスーティカル カンパニー インク． 粘膜送達を向上させるためのタイトジャンクション調節ペプチド化合物
EP1951200A2 (en) 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CA2631493A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7651770B2 (en) 2005-12-16 2010-01-26 The University Of Kansas Nanoclusters for delivery of therapeutics
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
CN101404980A (zh) 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
GB0621957D0 (en) 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
GB0700839D0 (en) 2007-01-17 2007-02-21 Braithwaite Philip Device
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
AU2008266948B2 (en) 2007-06-13 2012-08-23 Kirin-Amgen, Inc. IL-17 heteromeric receptor complex
JP2010533181A (ja) 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
AU2008279129A1 (en) 2007-07-24 2009-01-29 Nexbio, Inc. Technology for the preparation of microparticles
WO2009019598A2 (en) * 2007-08-03 2009-02-12 Dr. Reddy's Laboratories Ltd. Inhalation therapy for respiratory disorders
US8614255B2 (en) 2007-08-21 2013-12-24 Civitas Therapeutics, Inc. Pulmonary pharmaceutical formulations
US9358242B2 (en) 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US20110142914A1 (en) 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
EP2237788A4 (en) 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
DE102008004386A1 (de) 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
KR101835252B1 (ko) 2008-01-15 2018-03-06 유니베르시떼 드 스트라스부르 치료제로서 유용한 레조르실산 락톤의 합성
WO2009136976A2 (en) 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
EP2255797A4 (en) 2008-02-22 2011-09-07 Hanall Biopharma Co Ltd COMPOSITE PREPARATION
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
CA2720490A1 (en) 2008-04-04 2009-10-08 Irm Llc Compounds and compositions as itpkb inhibitors
US20090257957A1 (en) 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
KR20110045004A (ko) 2008-07-15 2011-05-03 쉐링 코포레이션 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
CA2729644C (en) 2008-07-18 2018-05-29 Prosonix Limited Process for improving crystallinity
WO2010011329A2 (en) 2008-07-23 2010-01-28 Map Pharmaceuticals, Inc. The delivery of powdered drug via inhalation
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
PE20120647A1 (es) 2009-03-13 2012-05-31 Nucitec Sa De Cv Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular
US20120046251A1 (en) 2009-04-06 2012-02-23 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
AU2010239396B2 (en) 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
WO2010131486A1 (en) 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
ES2662769T3 (es) 2009-05-18 2018-04-09 Adamis Pharmaceuticals Corporation Contadores de dosis de inhalador de polvo seco
AU2010249654B2 (en) 2009-05-18 2013-09-19 Adamis Pharmaceuticals Corporation Dry powder inhalers
JP2012528844A (ja) 2009-06-01 2012-11-15 バイオコピア リミテッド 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
RU2580890C2 (ru) * 2010-09-30 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Применение стеарата магния в составах сухого порошка для ингаляции
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
CN102058886A (zh) 2010-12-20 2011-05-18 云南白药集团无锡药业有限公司 医用粉雾剂及其应用
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
BR112013026313A8 (pt) 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US20120306613A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Sensor allocation
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
PH12014500508A1 (en) 2011-09-06 2014-05-12 Verona Pharma Plc Treating cough and tussive attacks
BR112014014594B1 (pt) 2011-12-16 2021-02-17 Indosys Limited dispositivo de liberação de medicamento seco em pó
US20130196906A1 (en) 2012-01-31 2013-08-01 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
NZ629438A (en) * 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
EP2831072B1 (en) 2012-03-26 2017-04-19 Arroyo BioSciences L.L.C. Novel sphingosine 1-phosphate receptor antagonists
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
CN111700879A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
SG11201407676VA (en) 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
US9993439B2 (en) 2012-06-20 2018-06-12 University Of Waterloo Mucoadhesive nanoparticle delivery system
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
WO2014053482A1 (en) 2012-10-03 2014-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists
WO2014074422A1 (en) 2012-11-07 2014-05-15 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HUE052275T2 (hu) 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
GB201305813D0 (en) 2013-03-28 2013-05-15 Vectura Ltd Compositions and methods
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
WO2015002703A1 (en) 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
JP6296371B2 (ja) 2013-12-23 2018-03-20 ウェン、シャオガンＷＥＮ， Ｘｉａｏｇｕａｎｇ 二層錠剤の調製方法
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
CN110724691A (zh) 2014-02-27 2020-01-24 阿勒根公司 补体因子Bb抗体
CN106715443A (zh) 2014-03-26 2017-05-24 坎格特生物技术制药有限责任公司 Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途
WO2015153838A1 (en) 2014-04-02 2015-10-08 Rogne Bioscience Inc. Methods and compositions for treating inflammatory disorders
WO2015155544A1 (en) 2014-04-10 2015-10-15 Patrick Crowley Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
KR20150127315A (ko) 2014-05-07 2015-11-17 삼성중공업 주식회사 밸러스트수 처리 장치
EP4218734A1 (en) * 2014-07-31 2023-08-02 Vectura Inc. Dry powder formulations for inhalation
US20180056022A1 (en) 2015-03-21 2018-03-01 James Zhou Liu Hand-actuated dry powder inhaler and its use
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
CN106619549B (zh) * 2017-01-03 2019-12-06 江苏吴中医药集团有限公司苏州制药厂 一种替格瑞洛与阿司匹林复合片剂及其制备方法
US10786456B2 (en) * 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JP7493449B2 (ja) * 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物
JP7690081B1 (ja) 2024-03-14 2025-06-09 ミサワホーム株式会社 モバイルユニットの連結構造

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521788A (ja) 2004-11-30 2008-06-26 ヴェクトゥラ リミテッド 医薬製剤
JP2017506252A (ja) 2014-02-20 2017-03-02 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ａｃｔａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｔｅｃｈｎｏｌｏｇｉｃａ ３３ （１９８７），ｐ．２１－２６
Ｊｏｕｒｎａｌ ｏｆ Ｔｈｅｒｍａｌ Ａｎａｌｙｓｉｓ ａｎｄ Ｃａｌｏｒｉｍｅｔｒｙ １１２ （２０１３），ｐ．４０７－４１９

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022137070A (ja) * 2017-09-22 2022-09-21 オティトピック インク． ステアリン酸マグネシウムを含む乾燥粉末組成物
JP7561162B2 (ja) 2017-09-22 2024-10-03 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物

Also Published As

Publication number Publication date
CN111315363A (zh) 2020-06-19
US12508227B2 (en) 2025-12-30
US20190336448A1 (en) 2019-11-07
MX2020002769A (es) 2020-07-20
CA3076353A1 (en) 2019-03-28
KR20230040375A (ko) 2023-03-22
MX2023006856A (es) 2023-06-22
AU2017432640B2 (en) 2023-11-30
KR20200090755A (ko) 2020-07-29
US20220016030A1 (en) 2022-01-20
JP2021502954A (ja) 2021-02-04
US10195147B1 (en) 2019-02-05
EP3684338A4 (en) 2021-06-23
JP7561162B2 (ja) 2024-10-03
WO2019059953A2 (en) 2019-03-28
KR102507987B1 (ko) 2023-03-21
CN115919780A (zh) 2023-04-07
CN111315363B (zh) 2022-10-11
AU2017432640A1 (en) 2020-03-19
WO2019059953A3 (en) 2019-09-26
KR102681843B1 (ko) 2024-07-05
JP2022137070A (ja) 2022-09-21
EP3684338A2 (en) 2020-07-29
US11077058B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
JP7561162B2 (ja) ステアリン酸マグネシウムを含む乾燥粉末組成物
KR100697479B1 (ko) 많은 치료학적 양의 에어로졸을 효과적으로 전달하는 방법
JP7623854B2 (ja) 乾燥粉末配合および使用方法
EP1531794B1 (en) Inhalable epinephrine
EP1589947B2 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
CN112656780A (zh) 用于吸入的干粉制剂
EA031566B1 (ru) Единичная лекарственная форма в форме композиции сухого порошка, применение единичной лекарственной формы и ингалятор сухого порошка, заполненный единичной лекарственной формой
KR102666667B1 (ko) 흡입용 건조 분말 제형
US10786456B2 (en) Inhaled aspirin and magnesium to treat inflammation
JP2019038857A (ja) レボドパの血漿濃度の患者間のばらつきの低減
CA2888979C (en) Reducing inter-patient variability of levodopa plasma concentrations
HK1253918B (en) Inhalable epinephrine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20211117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20211125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220620

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220627

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220629

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220715

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220721

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240521

R150 Certificate of patent or registration of utility model

Ref document number: 7493449

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150